Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alpine Immune Sciences Inc (NQ: ALPN )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, May 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Alpine Immune Sciences Inc

< Previous 1 2 3 4 Next >
What 11 Analyst Ratings Have To Say About Alpine Immune Sciences
Via Benzinga
ALPN Stock Earnings: Alpine Immune Sciences Beats EPS, Beats Revenue for Q1 2024
ALPN stock results show that Alpine Immune Sciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
3 Growth Stocks You’ll Kick Yourself for Not Buying Today
Netflix, Intuit, and Vertex Pharmaceuticals are three growth stocks to buy, each positioned for significant market share and returns. 
Via InvestorPlace
PTC Therapeutics Stock Sees IBD RS Rating Climb To 72
PTC Therapeutics stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 61 to 72. 
Via Investor's Business Daily
Sarepta Therapeutics Stock Shows Improved Technical Strength
The Relative Strength (RS) Rating for Sarepta Therapeutics stock headed into a new percentile Monday, as it got a lift from 70 to 73. 
Via Investor's Business Daily
$100B Vertex Pharma Working To Recreate $10B Cystic Fibrosis Success - This Time Focused On Pain Management Drugs
Unlock Vertex Pharmaceuticals' pioneering treatments, from the groundbreaking Trikafta for cystic fibrosis to the promising non-opioid painkillers. 
Via Benzinga
Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy?
Vertex is broadening its portfolio. 
Via The Motley Fool
Looking for Once-in-a-Generation Investment Opportunities? Here Are 3 Magnificent Stocks to Buy Right Now
These stocks could be near major inflection points. 
Via The Motley Fool
3 Relatively Safe Growth Stocks You Can Buy and Hold
Low risk and high-reward potential? These stocks could offer both. 
Via The Motley Fool
Does This Acquisition Make Vertex Pharmaceuticals Stock a Buy?
The biotech just added another potential growth driver to its pipeline. 
Via The Motley Fool
Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?
Discover three biotech stocks with explosive growth potential. Don't miss out on these great picks this year. 
Via InvestorPlace
Here's (at Least) 1 new Reason to Buy Vertex Pharmaceuticals Stock
Vertex just laid claim to an asset that might be very valuable. 
Via The Motley Fool
Could This Stock Be the Next Biotech Buyout?
Vertex Pharmaceuticals' $4.9 billion purchase of Alpine Immune Sciences probably won't be the last acquisition of a company focused on kidney disease. 
Via The Motley Fool
Stock Market Sends Mixed Signals; Nvidia, Inflation, Mideast Fears In Focus: Weekly Review
The stock market gave some bullish signs, with Nvidia rebounding, but the indexes generally fell for the week on inflation and Mideast fears. 
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
Stocks Surge, Goldgasms To Record High After "Adjusted" PPI Sparks Buying Frenzy
What started off as another ugly day with stocks tumbling and yields surging following yesterday's VaR-shock-inducing CPI print, quickly reversed after the market - in its infinite stupidity - took... 
Via Talk Markets
Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion, expanding into nephrology with promising APOL1-mediated kidney disease treatments. Analysts foresee significant revenue growth... 
Via Benzinga
Stocks Bounce Back With Tech, Gold Gaining After Modest Producer Inflation Data: What's Driving Markets Thursday?
Investors can breathe a sigh of relief on Thursday as last month’s Producer Price Index (PPI) inflation turned out slightly lower than expected, albeit with some caveats across different measures... 
Via Benzinga
Topics Economy
Exposures Interest Rates
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) rose sharply during Thursday’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today
Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease. 
Via InvestorPlace
Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
Novartis snagged a licensing deal with Arvinas worth up to $1.16 billion, while Janux is said to be exploring its options. 
Via Investor's Business Daily
Vertex Pharmaceuticals Moves Beyond $10B Cystic Fibrosis Franchise, Pays Around $5B For Kidney Disease Player Alpine Immune
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion in cash. Povetacicept, a potent dual antagonist of BAFF and APRIL, shows promise in IgA nephropathy. Transaction expected to... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Wall Street Braces For Another Red Day Ahead Of More Inflation Data While Bitcoin Holds Above $70K: Analyst Sees Any Pullback As 'Phenomenal Buying Opportunity'
The negative mood on Wall Street may persist as investors await the release of another inflation report, which will have significant implications for the near-term trend in cons 
Via Benzinga
Topics Economy
Exposures Interest Rates
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
We're starting off Thursday with a breakdown of all the biggest pre-market stock movers traders will want to keep an eye on this morning! 
Via InvestorPlace
Why Rallybio Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
Shares of Rallybio Corporation (NASDAQ: RLYB) rose sharply in today’s pre-market trading after the company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant... 
Via Benzinga
Why Bitcoin-Linked MicroStrategy Along With Adial Pharmaceuticals, Alpine Immune Sciences, Marin Software, And Tesla Are On Investors' Radars Today
On Wednesday, key U.S. stock indexes closed lower, as the Dow Jones Industrial Average fell by 1.1% to 38,461.51, the S&P 500 dropped nearly 1% to 5,160.64, and the Nasdaq ended the day down by 0.8% at... 
Via Benzinga
Topics Stocks
Exposures US Equities
Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion Deal
The companies expect the deal to close later this quarter. 
Via Investor's Business Daily
Why Is Kidney Disease-Focused Alpine Immune Sciences Stock Trading Higher On Wednesday?
Alpine Immune Sciences explores strategic options, potentially selling amid interest from buyers. The Seattle-based firm, with soaring stock up over 400%, evaluates various possibilities. 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.